David Schnell, M.D.

Managing Director, Prospect Venture Partners

David is a Managing Director of Prospect Venture Partners. David co-founded Prospect Venture Partners I, II, and III as dedicated life science funds with over $1 billion under management. David has been actively involved in the formation and growth of numerous successful biomedical and health care companies. He has lead investments and served on the Board of Directors of Gloucester Pharmaceuticals, Healtheon (NASDAQ: HLTH), Kythera Biopharmaceuticals, Lux Biosciences, Microcide Pharmaceuticals (NASDAQ: MCDE), Neurocrine Biosciences (NASDAQ: NBIX), NGM Biopharmaceuticals, Nora Therapeutics, Rinat Neuroscience (NYSE: PFE acquired), Senomyx (NASDAQ:SNMX), Trubion Pharmaceuticals (NASDAQ: TRBN) as well as several other privately held companies. David received an M.D. from Harvard Medical School, an M.A. in Health Services Research from Stanford University School of Medicine, and a B.S. in Biological Sciences from Stanford University.